Filtered By:
Drug: Beta-Blockers

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 494 results found since Jan 2013.

Impact of Gender on Type II Diabetes Glycemic and Cardiovascular Markers Control and Treatment
CONCLUSION: Both genders exhibited comparable HbA1c levels. Medical treatment optimization along with controlling both measured cardiovascular makers and laboratory result levels was based on comorbidities and complications rather than gender.PMID:33274898 | DOI:10.3923/pjbs.2020.1643.1649
Source: Pakistan Journal of Biological Sciences: PJBS - December 4, 2020 Category: Biomedical Science Authors: Khaled A Alswat Source Type: research

Effect of non-adherence of evidence-based medication prescribing on major adverse cardiovascular events among acute coronary syndrome patients
Background and Aims: Combination therapy with evidence-based medicines, including 4 groups of medication: dual antiplatelet, beta-blocker, ACEI /ARB, and statin, could reduce the risk of morbidity and mortality among patients with the acute coronary syndrome (ACS). This retrospective cohort study aimed to compare the risk of major adverse cardiovascular events (MACE) including cardiovascular death, myocardial infarction, unstable angina, and stroke during the first year of discharge between ACS patients received 4 groups and those did not receive at least 1 medication group.
Source: Atherosclerosis - December 1, 2020 Category: Cardiology Authors: S. Chinwong, M. Chommontha, S. Kammanat, A. Phrommintikul, D. Chinwong Source Type: research

Statins and beta blockers - The most frequently encountered potential prescribing omissions in rural Romanian elderly population
Background and Aims: Cardiovascular diseases (ischaemic heart diseases and stroke) are the leading cause of death in Romania, the death rate of ischaemic heart disease being three times higher than in European Union. The aim of this study was to identify potential prescribing omissions (PPOs) and to determine their prevalence based on the STOPP / START v.2, 2015, criteria for patients over the age of 65 years old.
Source: Atherosclerosis - December 1, 2020 Category: Cardiology Authors: V.O. Buda, O. Dalleur, A. Prelipcean, S. Buda, M. Andor, D.E. Baibata, A. Dohou, L. Petrescu, C. Cristescu Source Type: research

Beta-blockers in refractory ascites – is it truly the end of the road?
We read with great interest the study by Tellez et  al.1 highlighting mechanisms of hemodynamic alterations and associated renal dysfunction with the use of a 4-week non-selective beta-blocker (NSBB) therapy in refractory ascites (RA) and diuretic responsive ascites (DRA).1 They proposed ejection intra-ventricular pressure difference (EIVPD) as a n ovel load-independent measure that predicts LV systolic function decline better than standard load-dependent measures (ejection fraction and stroke volume).
Source: Journal of Hepatology - August 26, 2020 Category: Gastroenterology Authors: Rohit Mehtani, Akash Roy, Nipun Verma, Madhumita Premkumar, Virendra Singh Tags: Letter to the Editor Source Type: research

Transthyretin cardiac amyloidosis.
Authors: Eicher JC, Audia S, Damy T Abstract Transthyretin (TTR) cardiac amyloidosis results from the dissociation of the tetrameric, liver-synthetized transport protein, either because of a mutation (hereditary CA), or spontaneously due to ageing (wild type CA). Monomers self-associate into amyloid fibrils within the myocardium, causing heart failure, arrhythmias and conduction defects. This overlooked disease must be recognized in case of unexplained increased thickness of the myocardium, particularly in subjects of African descent, in patients with heart failure and preserved ejection fraction, and in those with...
Source: Revue de Medecine Interne - August 23, 2020 Category: Internal Medicine Tags: Rev Med Interne Source Type: research

Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials
Conclusion: Compared with other antihypertensive agents, beta-blockers appear to be substantially less protective against stroke and overall mortality. However, they exhibit a substantial risk-reducing ability for all events when prescribed to lower BP in patients with modest or more clear BP elevations, and therefore can be used as additional agents in hypertensive patients.
Source: Journal of Hypertension - August 13, 2020 Category: Cardiology Tags: REVIEWS AND META-ANALYSES Source Type: research